The University of Chicago Header Logo

Connection

Elaine Tanhehco to Animals

This is a "connection" page, showing publications Elaine Tanhehco has written about Animals.
Connection Strength

0.157
  1. Preconditioning reduces myocardial complement gene expression in vivo. Am J Physiol Heart Circ Physiol. 2000 Sep; 279(3):H1157-65.
    View in: PubMed
    Score: 0.012
  2. Sublytic complement attack reduces infarct size in rabbit isolated hearts: evidence for C5a-mediated cardioprotection. Immunopharmacology. 2000 Sep; 49(3):391-9.
    View in: PubMed
    Score: 0.012
  3. Free radicals upregulate complement expression in rabbit isolated heart. Am J Physiol Heart Circ Physiol. 2000 Jul; 279(1):H195-201.
    View in: PubMed
    Score: 0.012
  4. Therapeutic potential of complement inhibitors in myocardial ischaemia. Expert Opin Investig Drugs. 2000 May; 9(5):975-91.
    View in: PubMed
    Score: 0.012
  5. Acute cocaine exposure up-regulates complement expression in rabbit heart. J Pharmacol Exp Ther. 2000 Jan; 292(1):201-8.
    View in: PubMed
    Score: 0.012
  6. Preconditioning reduces tissue complement gene expression in the rabbit isolated heart. Am J Physiol. 1999 12; 277(6):H2373-80.
    View in: PubMed
    Score: 0.011
  7. The anti-factor D antibody, MAb 166-32, inhibits the alternative pathway of the human complement system. Transplant Proc. 1999 Aug; 31(5):2168-71.
    View in: PubMed
    Score: 0.011
  8. Reduction of myocardial infarct size after ischemia and reperfusion by the glycosaminoglycan pentosan polysulfate. J Cardiovasc Pharmacol. 1999 Jul; 34(1):153-61.
    View in: PubMed
    Score: 0.011
  9. Actin dynamics is rapidly regulated by the PTEN and PIP2 signaling pathways leading to myocyte hypertrophy. Am J Physiol Heart Circ Physiol. 2014 Dec 01; 307(11):H1618-25.
    View in: PubMed
    Score: 0.008
  10. Long-term pharmacological activation of PPARgamma does not prevent left ventricular remodeling in dogs with advanced heart failure. Cardiovasc Drugs Ther. 2007 Feb; 21(1):29-36.
    View in: PubMed
    Score: 0.005
  11. Long-term therapy with the acorn cardiac support device normalizes gene expression of growth factors and gelatinases in dogs with heart failure. J Heart Lung Transplant. 2005 Oct; 24(10):1619-25.
    View in: PubMed
    Score: 0.004
  12. Long-term effects of non-excitatory cardiac contractility modulation electric signals on the progression of heart failure in dogs. Eur J Heart Fail. 2004 Mar 01; 6(2):145-50.
    View in: PubMed
    Score: 0.004
  13. Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. Circ Res. 2003 Nov 28; 93(11):1095-101.
    View in: PubMed
    Score: 0.004
  14. Hypoxia, angiotensin-II, and norepinephrine mediated apoptosis is stimulus specific in canine failed cardiomyocytes: a role for p38 MAPK, Fas-L and cyclin D1. Eur J Heart Fail. 2003 Mar; 5(2):121-9.
    View in: PubMed
    Score: 0.004
  15. Cardiac contractility modulation with nonexcitatory electric signals improves left ventricular function in dogs with chronic heart failure. J Card Fail. 2003 Feb; 9(1):69-75.
    View in: PubMed
    Score: 0.004
  16. Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. Br J Pharmacol. 2003 Jan; 138(2):301-9.
    View in: PubMed
    Score: 0.004
  17. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation. 2002 Dec 03; 106(23):2967-72.
    View in: PubMed
    Score: 0.004
  18. Effects of long-term monotherapy with metoprolol CR/XL on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Cardiovasc Drugs Ther. 2002 Sep; 16(5):443-9.
    View in: PubMed
    Score: 0.003
  19. Effects of chronic neutral endopeptidase inhibition on the progression of left ventricular dysfunction and remodeling in dogs with moderate heart failure. Cardiovasc Drugs Ther. 2002 May; 16(3):209-14.
    View in: PubMed
    Score: 0.003
  20. Ex vivo reversal of heparin-mediated cardioprotection by heparinase after ischemia and reperfusion. J Pharmacol Exp Ther. 1999 Sep; 290(3):1041-7.
    View in: PubMed
    Score: 0.003
  21. Endotoxin disrupts the estradiol-induced luteinizing hormone surge: interference with estradiol signal reading, not surge release. Endocrinology. 1999 Jun; 140(6):2471-9.
    View in: PubMed
    Score: 0.003
  22. The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in the rabbit perfused heart. J Pharmacol Exp Ther. 1998 Jun; 285(3):987-94.
    View in: PubMed
    Score: 0.003
  23. Reduction of myocardial infarct size in vivo by carbohydrate-based glycomimetics. J Pharmacol Exp Ther. 1998 Jan; 284(1):427-35.
    View in: PubMed
    Score: 0.003
  24. Attenuation of interleukin-8 expression in C6-deficient rabbits after myocardial ischemia/reperfusion. J Mol Cell Cardiol. 1998 Jan; 30(1):75-85.
    View in: PubMed
    Score: 0.003
  25. Reviparin-sodium prevents complement-mediated myocardial injury in the isolated rabbit heart. J Cardiovasc Pharmacol. 1997 Nov; 30(5):658-66.
    View in: PubMed
    Score: 0.002
  26. Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. Br J Pharmacol. 1996 Mar; 117(6):1261-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.